GOSSAMER BIO, INC. Shares Issued, Shares, Share-based Payment Arrangement, Forfeited
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- GOSSAMER BIO, INC. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2023-09-30 was 0.00 shares.
- GOSSAMER BIO, INC. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2023-06-30 was 0.00 shares.
- GOSSAMER BIO, INC. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2023-03-31 was 0.00 shares.
- GOSSAMER BIO, INC. shares issued, shares, share-based payment arrangement, forfeited for the quarter ending 2021-12-31 was 25.38K shares.
| Period end | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 3 month | Shares Issued, Shares, Share-based Payment Arrangement, Forfeited 12 month |
|---|---|---|
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-09 | |
| 2022-12-31 | 0.00 shares 10-Q · filed 2023-11-09 | |
| 2021-12-31 | 25.38K shares derived: 10-Q 12 month − 10-Q 9 month · filed 2022-11-03 | 25.38K shares 10-Q · filed 2022-11-03 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 |